Catalent Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Catalent ha un patrimonio netto totale di $3.6B e un debito totale di $4.6B, che porta il suo rapporto debito/patrimonio netto a 126.9%. Le sue attività totali e le sue passività totali sono rispettivamente $9.8B e $6.1B. L'EBIT di Catalent è $6.0M rendendo il suo rapporto di copertura degli interessi 0. Ha liquidità e investimenti a breve termine pari a $289.0M.

Informazioni chiave

126.9%

Rapporto debito/patrimonio netto

US$4.57b

Debito

Indice di copertura degli interessi	0.02x
Contanti	US$289.00m
Patrimonio netto	US$3.60b
Totale passività	US$6.15b
Totale attività	US$9.75b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $2.6B ) di CTLT * superano le sue passività a breve termine ( $1.0B ).

Passività a lungo termine: Le attività a breve termine di CTLT * ( $2.6B ) non coprono le sue passività a lungo termine ( $5.1B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 118.9% ) di CTLT * è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di CTLT * è aumentato da 122% a 126.9% negli ultimi 5 anni.

Copertura del debito: Il debito di CTLT * non è ben coperto dal flusso di cassa operativo ( 5.9% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di CTLT * non sono ben coperti dall'EBIT ( 0 x copertura).

Catalent Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Catalent, Inc. announced delayed annual 10-K filing

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. announced delayed 10-Q filing

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. announced delayed annual 10-K filing

Catalent Regains Compliance with NYSE Continued Listing Standards

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Insider recently sold Mex$4.4m worth of stock

President recently sold Mex$10.0m worth of stock

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

President recently sold Mex$1.6m worth of stock

Insufficient new directors

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold Mex$1.3m worth of stock

Investor sentiment deteriorates as stock falls 36%

Investor sentiment improves as stock rises 50%

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Danaher Reportedly Expresses Takeover Interest in Catalent

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Insider recently sold Mex$796k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold Mex$3.2m worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Now 22% undervalued

Investor sentiment deteriorated over the past week

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Investor sentiment deteriorated over the past week

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Executive Chair of the Board recently sold Mex$80m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Catalent, Inc. Announces Board Changes

Insider recently sold Mex$251k worth of stock

Insider recently sold Mex$251k worth of stock

Insufficient new directors

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022